Stempeucel
Phase 3Cell therapy
Stempeucel is one of 33 biologic programs targeting Peripheral Arterial Disease. It is currently in Phase 3.
1
Indications
2
Total Trials
1
Active Trials
32
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
39 competitors in Peripheral Arterial Disease
#DrugCompanyPhaseTrials
1Bayer Aspirin
BayerApproved
Plavix
SanofiApproved
Brilinta
AstraZenecaApproved
Praluent
RegeneronApproved
Zyloprim
Jazz PharmaceuticalsApproved
Colcrys
Jazz PharmaceuticalsApproved
Zetia
OOrganon and Co
Approved
Pletal
OtsukaApproved
Lipitor
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Januvia
ZZydus Therapeutics Inc.
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Stempeucel. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Cell therapy[2]
- Highest Phase
- Phase 3[1]
- Company
- SStempeutics Research Pvt Ltd